Latest News

The FDA expanded the accelerated approval of sevabertinib to include treatment-naive adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain activating mutations.

The investigational IL-33–targeting monoclonal antibody tozorakimab reduced moderate-to-severe COPD exacerbations across 2 phase 3 trials, including among patients with low blood eosinophil counts.

Health systems are being urged to reconcile inventory immediately, as the affected vials are commonly stocked for anaphylaxis and septic shock emergencies.

The phase 3 DeLLphi-305 trial found that the first-line maintenance therapy improved overall survival in extensive-stage small cell lung cancer (ES-SCLC) compared with durvalumab alone.

A 5-level model for classifying AI-enabled pharmacy systems may help health systems advance to new levels of pharmacy autonomy.

Pharmacists rethink retirement: use compound growth, start early, and define the life you want—so your savings plan fits your future.

Lurking under the surface of inroads made toward better reimbursement and expanded scope of practice are major workforce supply challenges.

Camizestrant is the first cancer therapy guided by a ctDNA resistance mutation detected before imaging shows disease progression.

Preclinical research identifies tumor-secreted PRDX1 as a potential “redox checkpoint” that suppresses T-cell activity and may contribute to resistance to immune checkpoint inhibitors.

Clear governance, appropriate oversight, and alignment among technology, policy, and payment will be essential.

A single-center study found similar 12-month total weight loss whether or not patients used a glucagon-like peptide-1 (GLP-1) receptor agonist before surgery.

Long-lived monocyte-derived cells in the lung help sustain tissue-resident memory T cells after influenza infection, and researchers say the discovery could inform more effective nasal flu vaccines.

A prospective multicenter study found high response rates with first-line obinutuzumab plus bendamustine across several indolent B-cell lymphoma subtypes, although short follow-up and the absence of a comparator limit conclusions about long-term benefit.

An ifosfamide shortage prompts cancer treatment concerns and new importation efforts.

Blood Cancer Awareness Month highlights types of blood cancer and how pharmacists flag multiple myeloma symptoms early, speeding referral and care.

A prespecified analysis found the PCSK9 inhibitor reduced total events 20% in high-risk patients with no prior heart attack or stroke.

State boards of pharmacy are at the center of this issue and must be positioned and resourced to protect patient safety first.

Independent pharmacies should build documentation, watch rulemaking, and press for transparency terms in every contract renewal.

Zilganersen, an antisense oligonucleotide targeting glial fibrillary acidic protein, is cleared for pediatric and adult patients across all ages.

Pediatric and obstetric groups expand high-risk criteria and extend vaccination windows as federal vaccine guidance remains unsettled.

A real-world analysis of matched adults links glucagon-like peptide-1 (GLP-1) receptor agonist use to fewer major cardiovascular events, driven by a mortality benefit.